SCHEMBL2490118

SCHEMBL2490118

OC(c1ccccc1)(c1ccccn1)c1ccccn1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.75
L3MBTL1 Q9Y468 1/20 0.75
AHR P35869 2/20 0.54
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CFTR P13569 1/20 0.46
GOPC Q9HD26 1/20 0.46
HDAC6 Q9UBN7 3/20 0.45
CHRM3 P20309 1/20 0.43
CHRM2 P08172 1/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP19A1 P11511 2/20 0.42
BLM P54132 2/20 0.39
CYP2D6 P10635 1/20 0.39
SLC22A2 O15244 1/20 0.39
SLC22A1 O15245 1/20 0.39
PGR P06401 1/20 0.39
THRB P10828 1/20 0.39
ADRB3 P13945 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29410666 0.98 L3MBTL1 (0.78) SMN1; SMN2L3MBTL1AHRKMT2AMEN1
SCHEMBL912495 0.98 L3MBTL1 (0.78) SMN1; SMN2L3MBTL1AHRKMT2AMEN1
SCHEMBL4464386 0.87 SMN1; SMN2 (0.62) SMN1; SMN2L3MBTL1AHRCYP19A1CYP3A4
SCHEMBL2454601 0.86 L3MBTL1 (1.00) SMN1; SMN2L3MBTL1AHRKMT2AMEN1
SCHEMBL6579906 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRKMT2AMEN1
SCHEMBL11557390 0.84 AHR (0.60) SMN1; SMN2L3MBTL1AHRKMT2AMEN1
SCHEMBL15854868 0.82 AHR (0.81) SMN1; SMN2L3MBTL1AHRKMT2AMEN1
SCHEMBL22319803 0.82 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1AHRKMT2AMEN1
SCHEMBL3045407 0.82 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCYP19A1CYP3A4
SCHEMBL13714141 0.80 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1AHRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2380567-B1 MELANIN PRODUCTION INHIBITOR POLA CHEM IND INC (JP) 2019-01-16 EP disclosed
EP-2380567-B1 MELANIN PRODUCTION INHIBITOR POLA CHEM IND INC (JP) 2019-01-16 EP disclosed
EP-3009123-A1 MELANIN PRODUCTION INHIBITOR Pola Chemical Industries Inc. (JP) 2016-04-20 EP disclosed
EP-3009123-A1 MELANIN PRODUCTION INHIBITOR Pola Chemical Industries Inc. (JP) 2016-04-20 EP disclosed
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2015-11-19 US disclosed
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2015-11-19 US disclosed
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2015-11-19 US disclosed
EP-2845587-A2 Melanin production inhibitor Pola Chemical Industries Inc. (JP) 2015-03-11 EP disclosed
EP-2845587-A2 Melanin production inhibitor Pola Chemical Industries Inc. (JP) 2015-03-11 EP disclosed
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2014-12-11 US disclosed
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2014-12-11 US disclosed
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2014-12-11 US disclosed
US-8846012-B2 Melanin production inhibitor POLA CHEMICAL INDUSTRIES INC. (JP) 2014-09-30 US disclosed
US-8846012-B2 Melanin production inhibitor POLA CHEMICAL INDUSTRIES INC. (JP) 2014-09-30 US disclosed
US-8846012-B2 Melanin production inhibitor POLA CHEMICAL INDUSTRIES INC. (JP) 2014-09-30 US disclosed
EP-2380567-A1 MELANIN PRODUCTION INHIBITOR Pola Chemical Industries Inc. (JP) 2011-10-26 EP disclosed
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2011-10-06 US disclosed
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2011-10-06 US disclosed
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR TYR, F12, TH SMN1; SMN2 3632/4885L3MBTL1 895/4885AHR 92/4885
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR TYR, MC1R, F12 SMN1; SMN2 3663/4885L3MBTL1 644/4885AHR 65/4885
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR TYR, F12, MC1R SMN1; SMN2 3592/4885L3MBTL1 680/4885AHR 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.